The Use of RWE in ICER Evaluations: What It Means for Life Sciences Companies
Real-world evidence (RWE) has been gaining acceptance at a rapid rate in many areas of the life sciences industry including R&D, epidemiology, outcomes research, and commercial groups. The COVID-19 pandemic and resulting research to find treatments and vaccines has accelerated the growth and adoption of RWE as well. The Institute for Clinical and[…]
Leveraging RWD in Observational Studies: Understanding the Implications of Time-Related Biases
A Q&A with Samy Suissa, PhD Dr. Samy Suissa is a Co-Founder and Principal Investigator of the Canadian Network for Observational Drug Effect Studies (CNODES). He is Director of the Centre for Clinical Epidemiology, Lady Davis Institute for Medical Research at the Jewish General Hospital and Professor, Departments of Epidemiology and Biostatistics[…]
Innovating RWE Organizations: Learning from the Past and Looking to the Future
A Q&A with Christopher Boone, PhD, FACHE, FHIMMS Christopher Boone, PhD, is Vice President, Global Head of Health Economics and Outcomes Research at AbbVie. He is also an adjunct assistant professor of health administration at the New York University's Robert F. Wagner Graduate School of Public Service, an active board member of several health[…]
Pharma Commercial Teams: Building an Analytics Culture as a Driver of Competitive Advantage
This is the second in a two-post series on driving transformation and competitive advantage through analytics for life sciences commercial teams.
Viewpoint: Life Sciences Should View Commercial Analytics Teams as a Revenue Generator
A Q&A with Vijay Raghavan, Associate Vice President, Market Analytics and Business Insights, AbbVie Vijay Raghavan is an Associate Vice President, Market Analytics and Business Insights at AbbVie. He was previously Head of Marketing Analytics for Allergan and was Program Committee Lead and Membership Chair for the Pharmaceutical Management Science[…]
How are Data Networks and International Collaboration Furthering Epidemiologic Research? A Q&A with Samy Suissa, PhD
Dr. Samy Suissa is a Co-Founder and Principal Investigator of the Canadian Network for Observational Drug Effect Studies (CNODES). He is Director of the Centre for Clinical Epidemiology, Lady Davis Institute for Medical Research at the Jewish General Hospital and Professor, Departments of Epidemiology and Biostatistics and of Medicine, McGill[…]
Interview with Dr. Mark Friedman on Covid-19 Complications and the Use of Real-World Data
Mark Friedman is VP of Medical Affairs for Panalgo. He is an internist with over 20 years of clinical and pharmacoeconomics consulting experience. He has management experience in the formulary and managed care implementation processes and also plays a major role in the design and implementation of clinically-oriented outcomes research studies,[…]
You Can Influence ICER Recommendations, You Just Need the Right Evidence
It’s difficult to dispute the findings of an advisory group which is widely accepted as the authority, especially when it comes to evaluating the value of different therapeutic interventions. The cost of drugs in the U.S. has been a hot button topic in recent years, so healthcare industry stakeholders are increasingly looking for objective[…]
Scaling Analytics Across Your Commercial Teams as a Driver of Competitive Advantage
First in a two-part blog series on how life sciences commercial teams can drive competitive advantage through analytics The investment in data and analytics by life sciences organizations is not new and the advantages are continually touted. A recent article from McKinsey estimates predictive analytics and data visualization can optimize life[…]
BHE is Now Panalgo: Why We Changed Our Name and Brand
In 1996, I started Boston Health Economics (BHE) to provide professional research services to the life sciences industry, including economic modeling, database analyses and strategic consulting. For more than two decades we have had the privilege of serving the industry’s leading life sciences organizations.